Elevated CCL19 after Completion of Therapy for Acute Lyme Disease Identifies Patients at Risk for Development of Post-treatment Lyme Disease Syndrome Who Will Benefit from Further Antibiotic Therapy

Case ID:
C13517
Disclosure Date:
4/6/2015
Description:
The chemokine CCL19 has been identified in acute pre-treatment samples from patients with Lyme disease and distinguishes acutely infected patients from controls. In addition we have demonstrated that a subset of patient continue to have elevated levels of CCL19 for up to 6-12 months post-treatment. In addition, the measurement of an elevated CCL19 immediately after the completion of antibiotic therapy identifies those at high risk of having persistent symptoms. This high risk population is a candidate for further antibiotic therapy to prevent the development of long term complications of PTLDS.
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Elevated CCL19 after Completion of Therapy for Acute Lyme Disease Identifies Patients at Risk for Development of Post-treatment Lyme Disease Syndrome Who Will Benefit from Further Antibiotic Therapy ORD: Ordinary Utility United States 15/131,063 4/18/2016     Pending
Inventors:
Category(s):
For Information, Contact:
Christine Joseph
cjoseph6@jhmi.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum